Lumosa Therapeutics (6535) reported revenue of NT$78,000 for Oct 2026, -54.9% year on year and -63.0% from the previous month. Revenue for Jan–Oct 2026 was NT$19 million (-17.1% year on year).
In Oct 2026, it ranked No. 152 by revenue among 160 Biotech & Medical companies.
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$78,000 | -54.9% | -63.0% |
| Sep 2026 | NT$211,000 | -95.1% | -97.7% |
| Aug 2026 | NT$9.1 million | +5,135.8% | +11,512.8% |
| Jul 2026 | NT$78,000 | -98.9% | -98.4% |
| Jun 2026 | NT$5 million | +233.5% | +6,275.6% |
| May 2026 | NT$78,000 | -64.5% | +0.0% |
| Apr 2026 | NT$78,000 | -83.4% | -84.5% |
| Mar 2026 | NT$503,000 | -94.3% | +1,576.7% |
| Feb 2026 | NT$30,000 | -25.0% | -99.2% |
| Jan 2026 | NT$4 million | +9,777.5% | -71.7% |
| Dec 2025 | NT$14 million | -19.3% | +7,971.7% |
| Nov 2025 | NT$173,000 | -95.8% | +0.0% |
| Oct 2025 | NT$173,000 | +332.5% | -95.9% |
| Sep 2025 | NT$4.3 million | +1,056.9% | +2,367.6% |
| Aug 2025 | NT$173,000 | +332.5% | -97.6% |
| Jul 2025 | NT$7.3 million | +21.8% | +387.1% |
| Jun 2025 | NT$1.5 million | +297.6% | +577.7% |
| May 2025 | NT$220,000 | -94.9% | -53.1% |
| Apr 2025 | NT$469,000 | -87.9% | -94.7% |
| Mar 2025 | NT$8.8 million | +2,250.9% | +21,940.0% |
| Feb 2025 | NT$40,000 | +0.0% | +0.0% |
| Jan 2025 | NT$40,000 | -99.0% | -99.8% |
| Dec 2024 | NT$17.3 million | +93.1% | +315.2% |
| Nov 2024 | NT$4.2 million | -59.4% | +10,317.5% |
| Oct 2024 | NT$40,000 | +0.0% | -89.2% |
Jan–Oct 2026 cumulative: NT$19 million (-17.1% YoY)
Other Biotech & Medical companies
Compare with peers: Lumosa Therapeutics vs PEC / Lumosa Therapeutics vs Lotus Pharm / Lumosa Therapeutics vs Bora
| Company | Revenue | YoY |
|---|---|---|
| PEC | NT$2.84 billion | +102.0% |
| Lotus Pharm | NT$2.13 billion | -22.5% |
| Bora | NT$1.99 billion | +15.9% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| EXCELSIOR | NT$1.02 billion | +38.6% |
| PEGAVISION | NT$793 million | +13.0% |
| Synmosa Biopharma | NT$766.6 million | +41.2% |
| Y.S.H. | NT$749.4 million | +4.4% |
Company remark (original Chinese)
本月勞務收入較去年同期減少
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16